Why the study?
Does continuous perioperative infusion of diltiazem improve antiischemic and antiarrhythmic outcomes compared to nitroglycerin in patients undergoing elective coronary artery bypass grafting?
Population
120 patients undergoing elective coronary artery bypass grafting (CABG)
Comparison
Continuous perioperative infusion of diltiazem… vs Continuous perioperative infusion of…
Design
RCT, Randomized
Follow-up
Up to 24 hours postoperatively
Authors
Loading...
Supports diltiazem over nitroglycerin for perioperative ischemia and AF reduction in CABG; extends RCT evidence for calcium-channel blockers in cardiac surgery.
Does continuous perioperative infusion of diltiazem improve antiischemic and antiarrhythmic outcomes compared to nitroglycerin in patients undergoing elective coronary artery bypass grafting?
Continuous perioperative infusion of diltiazem provides potent antiischemic and antiarrhythmic protection without adversely affecting hemodynamics in patients undergoing elective CABG.
Seitelberger et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: